drugset / Trial / NCT00347139

Repeat Doses Of A New Medication (GW642444) In Asthmatic Patients

NCT00347139

Phase 2 Completed 55 enrolled GlaxoSmithKline
RandomizedCrossoverTriple-blindTreatment

Summary

In order to obtain information on a wider range of doses of GW642444 (a possible new medication to treat asthma) than has been previously examined in asthmatic patients, this current study will be conducted at doses of 25 100 and 400 mcg of GW642444 and will be compared with salmeterol (50 mcg twice daily). This study will be conducted in a similar manner to a study that has already been completed (study number B2C101762) which examined repeat doses of 50, 100 and 200 mcg of GW642444. The data obtained will compliment the data from study B2C101762 and will provide confidence (or not) that the desired bronchodilation can be achieved and maintained without undesirable side effects.

Timeline

Start
2006-05-23
Primary completion
2007-01-10
Completion
2007-01-10

Drugs

EvaluationDrugModalityDoseRoute
Comparator Salmeterol Other / unclassified 50 ug
Subject Vilanterol Other / unclassified 25 ug Inhaled
Subject Vilanterol Other / unclassified 100 ug Inhaled
Subject Vilanterol Other / unclassified 400 ug Inhaled